Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Center For Excellence In Eye Care |
---|---|
Information provided by: | Center For Excellence In Eye Care |
ClinicalTrials.gov Identifier: | NCT00469781 |
The objective of this study is to determine if twice-daily dosing of prednisolone (Pred Forte) is as effective as four-times-daily dosing of prednisolone for the prevention of retinal thickening and cystoid macular edema (CME) when either regimen is used concomitantly with twice-daily bromfenac.
Condition | Intervention | Phase |
---|---|---|
Cystoid Macular Edema, Retinal Thickening |
Drug: 2. Xibrom (Bromfenac) Drug: 1. Pred Forte |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Investigator), Active Control, Parallel Assignment |
Enrollment: | 95 |
Study Start Date: | May 2007 |
Study Completion Date: | September 2008 |
Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: 1. Pred Forte
Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks. Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks. |
2 |
Drug: 2. Xibrom (Bromfenac)
Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
· Male or female > 18 years of age scheduled to undergo cataract surgery
Exclusion Criteria:
· Known contraindication to any study medication or any of their components
United States, Florida | |
The Center for Excellence in Eye Care | |
Miami, Florida, United States, 33176 |
Principal Investigator: | Carlos Buznego, MD | The Center for Excellence in Eye Care |
Responsible Party: | The Center for Excellence in Eye Care ( Carlos Buznego, MD ) |
Study ID Numbers: | 5306 |
Study First Received: | May 4, 2007 |
Last Updated: | September 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00469781 |
Health Authority: | United States: Institutional Review Board |
Methylprednisolone Eye Diseases Edema Macular Degeneration Retinal Degeneration Methylprednisolone acetate Prednisolone acetate |
Macular Edema Signs and Symptoms Bromfenac Prednisolone Retinal Diseases Retinal degeneration Methylprednisolone Hemisuccinate |
Anti-Inflammatory Agents Sensory System Agents Analgesics, Non-Narcotic Therapeutic Uses Physiological Effects of Drugs Anti-Inflammatory Agents, Non-Steroidal |
Peripheral Nervous System Agents Analgesics Antirheumatic Agents Central Nervous System Agents Pharmacologic Actions |